Current status and future prospects for the treatment of antiphospholipid syndrome.

about

The Role of TLR4 on B Cell Activation and Anti-β2GPI Antibody Production in the Antiphospholipid Syndrome

P2860

Q28069430-7CEB5F07-6BE2-44FA-A9DC-3E5E47A71815

P2860

Current status and future prospects for the treatment of antiphospholipid syndrome.

Item

http://www.wikidata.org/entity/Q38818425

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Current status and future prospects for the treatment of antiphospholipid syndrome.

@en

type

Item

label

Current status and future prospects for the treatment of antiphospholipid syndrome.

@en

prefLabel

Current status and future prospects for the treatment of antiphospholipid syndrome.

@en

P1476

Current status and future prospects for the treatment of antiphospholipid syndrome.

@en

P2093

Ahlam Al Marzooqi

http://www.w3.org/2001/XMLSchema#string

Alessia Leone

http://www.w3.org/2001/XMLSchema#string

Jamal Al Saleh

http://www.w3.org/2001/XMLSchema#string

P2860

Belimumab in systemic lupus erythematosus

A Novel Dimeric Inhibitor Targeting Beta2GPI in Beta2GPI/Antibody Complexes Implicated in Antiphospholipid Syndrome

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals

Eculizumab and renal transplantation in a patient with CAPS

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents.

Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.

P304

927-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/1744666X.2016.1178573

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Munther A. Khamashta

P577

2016-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27117597

http://www.w3.org/2001/XMLSchema#string

Current status and future prospects for the treatment of antiphospholipid syndrome.

about

P2860

P2860

Current status and future prospects for the treatment of antiphospholipid syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698